Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
about
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects.How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer.
P2860
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@en
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@nl
type
label
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@en
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@nl
prefLabel
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@en
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@nl
P2093
P2860
P356
P1476
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
@en
P2093
Anne Stilman
Caroline Fradette
Fernando Tricta
Michael Spino
Shalini Jayashankar
Vincent Pichette
Yu Chung Tsang
Éric Sicard
P2860
P304
P356
10.1111/BCP.13037
P407
P577
2016-06-08T00:00:00Z